Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations: 2017-2025

Historic Income from Continuing Operations for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Income from Continuing Operations fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 54.83%. This contributed to the annual value of -$297.4 million for FY2024, which is 42.19% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Income from Continuing Operations of -$130.1 million as of Q3 2025, which was down 12.48% from -$115.7 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Income from Continuing Operations peaked at -$22.9 million during Q1 2021, and registered a low of -$130.1 million during Q3 2025.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Income from Continuing Operations value was -$74.0 million (recorded in 2024), while the average stood at -$77.2 million.
  • Data for Crinetics Pharmaceuticals' Income from Continuing Operations shows a maximum YoY crashed of 75.14% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Income from Continuing Operations stood at -$26.1 million in 2021, then slumped by 75.14% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then tumbled by 43.69% to -$80.4 million in 2024, then tumbled by 69.33% to -$130.1 million in 2025.
  • Its Income from Continuing Operations stands at -$130.1 million for Q3 2025, versus -$115.7 million for Q2 2025 and -$96.6 million for Q1 2025.